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workbook. Results: Of the 71 STAs published, ACDs were produced for 60 technolo-
gies, while 11 (15%) proceeded straight to FAD. All submissions which proceeded 
directly to FAD were recommended (full or optimised) in the final guidance. Twelve 
STAs (20%) received a “minded no” at ACD; however, 11 of these (92%) were reversed 
within the FAD on the basis of additional data provided by the manufacturers in 
the form of economic analyses (n= 5) or patient access schemes (PAS) (n= 6). Of the 
35 “not recommended” at ACD, 15 (43%) were ultimately recommended within the 
FAD through the introduction or revision of a PAS and/or submission of additional 
analyses. ConClusions: If manufacturers can demonstrate a robust clinical and 
economic argument in their initial submission the chances of a FAD being produced 
without the requirement of an ACD are greatly increased. Furthermore, ACD deci-
sions can also be overturned; technologies which receive a “minded no” or “not 
recommended” at ACD stage can achieve a recommendation at FAD by presenting 
additional analyses or introducing/modifying a PAS.
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ComParison of Drug assessments in franCe, germany anD tHe uniteD 
KingDom: is euroPean Hta a reality?
Troubat A., Perrin L.
IMS Health, PARIS LA DEFENSE, France
objeCtives: In 2006, the EUnetHTA project was launched. One of its main strategic 
objectives was to strengthen the link between HTA and health care policy making 
in the EU. Seven years after EUnetHTA establishment, the objective of this study 
was to compare HTA agencies’ assessments in France, Germany and UK, focusing 
on method and outcomes. Methods: Scope of the study was all the products 
getting a positive opinion from CHMP during two years, starting at January 1, 2011. 
Comparison between assessments was made for products assessed by the three 
HTA agencies: IQWiG, NICE, and HAS. Results: A total of 87 drugs were included in 
this study. 11 (13%) have been assessed by the three agencies. Among these drugs, 
more than 50% (6) were cancer treatment. HAS was the first to assess drug in 6 cases 
(mean delay between CHMP positive opinion and assessment: 223 days), followed 
closely by IQWiG (242 days), then by NICE (354 days). IQWiG segmented the patient 
population defined by the manufacturer into different sub-populations in 6 assess-
ments, HAS in 2, NICE never. NICE was the only agency who did not recommend a 
drug for cost-effectiveness reasons (2 assessments). In three assessments, IQWiG 
concluded that there was no benefit proven for the whole population; regarding 
the same drugs, HAS concluded there was minor improvement in actual benefit 
twice. ConClusions: Some major trends emerge in the assessments studied: use 
of indirect comparisons, added therapeutic value weighted by severity and fre-
quency of side effects and uncertainty. Nevertheless, comparator choices, perception 
of clinical benefits and risks, budget impact and overall method still differ between 
the three HTA agencies studied, leading to different outcomes for drugs assessed.
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objeCtives: To examine whether the Delphi method can provide a convenient 
tool for selecting medical technologies for inclusion in the National List of Health 
Services (NLHS) in Israel under a pre-defined budget constraint. Methods: The 
Delphi method was applied in two groups: medical specialists (oncologists and 
cardiologists) and observers in the NLHS committee. Participants in each group 
were anonymously asked to choose five of ten suggested technologies from the list 
of technologies submitted for inclusion in the 2012 NLHS and rank them accord-
ing to importance. Subsequently, the participants repeated the experiment after 
receiving aggregated feedback on the relative ranking of each technology within the 
same group after the first round. Comparison of the results was performed using 
descriptive statistics and non-parametric tests. Results: After two rounds of the 
experiment, observers and medical specialists reached agreement on four of the 
five highest ranked technologies in each field (oncology and cardiology) regarding 
their importance to be included in the NLHS. Three of these four technologies were 
indeed included in the NLHS for 2012. ConClusions: The Delphi method is one of 
the best-known techniques to control group interaction and reach a consensus by 
utilizing the expertise of committee members. The study demonstrated the feasibil-
ity using the Delphi method for ranking health care technologies.
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objeCtives: In the lack of head-to-head comparative trials to demonstrate the effi-
cacy of new treatments, it is common to use network meta-analysis (NMA), includ-
ing indirect treatment comparison (ITC) or combine direct and indirect evidence 
through mixed treatment comparison (MTC). Due to the increasing number of drugs 
approved for the same indication and the increasing complexity of networks for 
treatments comparisons, new methods of MTC taking into account all the com-
parisons have aroused. Health Technology Assessment (HTA) bodies increasingly 
demand NMA although different recommendations about the methodologies to be 
applied exist. This study aims to review recommendations regarding ITCs and MTCs 
among the main HTA bodies. Methods: A review of methodologies for drug com-
parison recommended by the main HTA bodies was performed. Recommendations 
related to evidence identification methods, assessment of homogeneity of studies 
and populations to be combined and statistical approach for the analysis were also 
reviewed. Results: A systematic literature search is a prerequisite for most HTA bod-
zations studied. The transparency index scores were as follows: Institut für Qualität 
und Wirtschaftlichkeit im Gesundheitswesen/Gemeinsamen Bundesausschusses 
(Germany), National Institute for Health and Care Excellence (UK), pan-Canadian 
Oncology Drug Review (Canada), Common Drug Review (Canada), Pharmaceutical 
Benefits Advisory Committee (Australia), Comissão Nacional de Incorporação 
de Tecnologias (Brazil), Haute Autorité de Santé (France), Agencia de Evaluación 
de Tecnologias Sanitarias (Spain), and Agenzia Italiana del Farmaco (Italy) were 
97%, 96%, 91%, 83%, 78%, 70%, 67%, 53%, and 25%, respectively. ConClusions: 
Transparency amongst HTA organizations is progressively becoming the interna-
tional standard. However, the extent of transparent processes and procedures proves 
to be heterogeneous amongst international review organizations.
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objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold generally understood to be £30,000 for NICE 
(England), £20,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), and 
AUS$42,000 for PBAC (Australia). To help inform future submissions, we assessed 
the rationale provided by the four HTA agencies when submissions were rejected 
despite the reported ICERs being lower than these thresholds. Methods: All HTA 
appraisals from January 2000 to May 2013 from NICE, SMC, CADTH, and PBAC were 
included in the analysis. Multiple technology appraisals, resubmissions, vaccination 
programmes, requests for advice, and submissions for which an ICER could not be 
determined were excluded from the analysis. The full responses of the remaining 
appraisals were reviewed, with the submitted ICER, recommendation, and reason-
ing behind the recommendation extracted. Results: A total of 594 submissions 
met the inclusion criteria. 354 submissions across the four HTA bodies included a 
lower-than-threshold ICER, with 107 (30.2%) of these submissions rejected. Across 
the agencies, the most common reasons for rejection were use of an inappropriate 
patient population or comparator (45/107), uncertainty regarding the clinical ben-
efits (32/107), and use of economic evidence that was not sufficiently robust (40/107). 
The reasons for rejection were consistent across the four agencies, with a similar 
proportion basing their decision at least partly on one of the three reasons provided 
above: NICE (92.9%), SMC (92.0%), CADTH (93.3%), PBAC (93.8%). ConClusions: A 
large proportion of submissions were rejected despite ICERs below the threshold. 
In instances where decisions went against the ICER thresholds, there was a clear 
tendency for identifiable problems with the clinical and economic assumptions to 
diminish the reliability of the ICERs presented. This result highlights that a lower-
than-threshold ICER is not enough for a positive recommendation and manufac-
turers must support their submission with accurate and reliable data to achieve a 
favourable outcome.
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objeCtives: A new drugs’ innovation benefit is commonly evaluated, both in 
Europe and the USA. Most of the new pharmaceutical launches have to be evalu-
ated on the level of innovation that they offer as part of the market access process. 
The objective of this abstract is to give an example of the variability that emerges 
in the innovation scores given by the Italian agency, AIFA, as compared to those of 
France, Germany and the USA. Methods: Drugs listed on the AIFA website as show-
ing potential or important innovation, were used as a benchmark to measure how 
innovation benefit assessments performed in France, Germany and the USA deviate. 
The innovation benefit was measured through: the ASMR score (Amélioration du 
Service Médical Rendu) in France, as published on the HAS website (Haute Autorite’ 
de Sante’); the level of additional benefit in Germany, as published on the G-BA 
website (Gemeinsame Bundesausschuss); the type of approval procedure as pub-
lished on the FDA (Food and Drug administration) website. In the case of the USA, 
standard approval vs. priority review was used as a proxy measure of the level of 
innovation. Results: The results of the innovation benefit’s evaluations performed 
in France, Germany and the USA differ from those performed by AIFA in 74%, 33% 
and 58% of cases respectively. The lower percentage in Germany is due to lim-
ited available information compared to other markets. ConClusions: The level 
of variability that exists between the outcomes of the innovativeness evaluation 
performed in different countries suggests that although the definition of innova-
tion may appear straightforward, it is open to different interpretations by different 
health care systems.
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objeCtives: The National Institute for Health and Care Excellence (NICE) estab-
lished the Single Technology Appraisal (STA) programme to evaluate the clinical 
and cost-effectiveness of medical technologies and provide mandatory guidance 
on how they should be used within the National Health Service (NHS) in the UK. The 
objective of this analysis is to explore how NICE advice differs between preliminary 
and final guidance in the STA process and identify actions manufacturers could 
take to increase their chances of a successful submission. Methods: For STAs 
published between February 2010 and May 2013, the appraisal consultation docu-
ment (ACD) and final appraisal determination (FAD) were identified. The guidance 
issued in these documents was compared and contrasted, and the key clinical and 
economic evidence that affected recommendations were extracted into an Excel 
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the assessments with an ASMR I, II or III. 70% (n = 49) of the remaining evaluations 
where ASMR IV or V. ConClusions: In the first six years mAbs were perceived as 
a disruptive innovation to a significant proportion of ASMRs between I and III as 
a reward for research and development efforts of the manufacturer. This research 
suggest that mAbs manufacturers no longer benefit from a ‘first mover’ advantage 
and may face higher scrutiny from the TC and greater price pressure from the 
French pricing committee.
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objeCtives: Small-Medium Enterprises (SMEs) should assess the potential profit-
ability of new medical devices early in their development. This can be achieved 
via early-stage health technology assessments (HTAs). However, many SMEs 
will not have the skills necessary to undertake these HTAs, so tools and frame-
works that aid this process are likely to be beneficial. A systematic review of the 
literature was undertaken to identify resources that can facilitate early-stage 
HTAs. Methods: Electronic databases, such as MEDLINE and ECONLIT, were 
searched in February 2013. Papers were included if they met all of the five selec-
tion criteria used. Results: Of the 4729 papers identified, ten were included in 
the final analysis. Only one interactive tool, a decision analytic model which is 
operational via Microsoft Excel, was identified. Of the remaining nine articles, five 
were classified as frameworks. Of these five articles, the most comprehensive out-
lines a multi-criteria decision analysis (MCDA) value matrix. The final three articles 
included in the final analysis contained descriptive methods with information that 
was considered useful. ConClusions: The resources available to aid the undertak-
ing of early-stage HTAs is very limited. Ideally, an interactive spreadsheet tool that 
generates intuitive results would be available. However, the one identified tool is 
too inflexible and most users would struggle to find accurate data to populate it. 
Unfortunately, these issues are likely to be endemic to any interactive tool for early 
modelling. As such other guidance, including frameworks, may be more useful if 
they are comprehensive. Only the MCDA framework article contained methods that 
the authors of this article considered comprehensive, and the use of MCDA for early-
stage HTAs has its own issues. Therefore, there may be a place in the literature for 
more complete pieces of guidance to undertaking early-stage HTAs.
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objeCtives: The Medical Technologies Evaluation Programme (MTEP) was 
established to promote the uptake of innovative medical technologies through the 
publication of Medical Technology Guidance (MTG) by the National Institute for Health 
and Care Excellence (NICE) to the National Health Service (NHS) in the UK. The objec-
tive of this analysis is to report data on the MTEP, which are not currently collated 
on the NICE website, in order to provide insights to manufacturers on the process, 
outcomes and implementation of guidance. Methods: Information published on 
the NICE website was used to identify notified technologies, the proportion routed to 
the MTEP, and the subsequent NICE recommendations. Results: Between January 
2010 and December 2012, 102 technologies were notified to the MTEP. Of these noti-
fications, 21 technologies were routed to MTEP and 15 were routed to the diagnostics 
assessment programme (DAP), giving a routing rate of 20% and 15%, respectively. Of 
the 21 technologies routed to MTEP, 13 technologies have had guidance issued: 10 
(77%) had a positive recommendation and 3 (23%) were not recommended for use in 
the NHS. Whilst a positive recommendation for use is likely to encourage uptake, it is 
not guaranteed. Following a positive MTEP recommendation for CardioQ-oesophageal 
doppler monitor (ODM), the implementation levels were relatively low (31% increase 
in use). ConClusions: Many of the notified technologies are not selected at notifi-
cation stage. However, once selected and routed to MTEP, most technologies receive 
some form of positive recommendation. Evidence on implementation levels following 
a positive recommendation by the NICE MTEP indicates that the implementation of 
guidance by the NHS may not always be optimal. The new NICE Health Technology 
Adoption Programme should help to improve implementation levels in the future. 
To ensure optimal implementation, manufacturers should consider developing tools 
to support the uptake of technologies alongside a NICE positive recommendation.
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objeCtives: Often positive reimbursement decisions are only achieved after 
multiple submissions. Multiple submissions can delay patient access to neces-
sary therapies and be costly for the manufacturer. This study analyzes the number 
of submissions needed to gain a positive decision and determines the lag time 
between the first submission and the positive decision. Methods: The data cov-
ered three agencies: SMC, PBAC, and CADTH’s Common Drug Review. The reviews 
spanned 23 disease conditions and included 396 Health Technology Assessments 
(HTAs). Results: A positive decision was achieved after the first submission in 50% 
of the HTAs analyzed. At 1.57 submissions, PBAC had the highest average number of 
submissions needed to achieve a positive decision. PBAC’s average was statistically 
higher than that of both CADTH and SMC (p< 0.001). On average, CADTH and SMC 
needed 1.17 and 1.16 submissions, respectively, to obtain a positive decision. Also, 
for drugs that were resubmitted, it took on average 430, 924 and 1,189 days to gain a 
positive decision from SMC, CADTH, and PBAC. For CADTH and SMC, there appears 
to be a modest linear relationship between the number of resubmissions needed 
ies, as well as demonstrating homogeneity and consistency among studies. Regarding 
to the statistical analysis, Bucher’s method is the most commonly used and is recom-
mended by most HTA bodies for indirect comparisons. Nevertheless, some HTA bodies 
(e.g. HAS, SMC), EUnetHTA and ISPOR Task Force on Indirect Treatment Comparisons 
consider that even if some direct evidence is available it is appropriate to validate the 
results using MTCs. According to these institutions, Bucher’s method is not appropri-
ate for the analysis of complex networks, while Bayesian approach is a more com-
prehensive method that can include meta-regression and study-level covariates. The 
use of the non-appropriate methods can derive to biased results. ConClusions: 
Methodology used for NMA should include all available evidence. Due to the increas-
ing complexity of network patterns, Bayesian analysis better meets HTA needs than 
the Bucher’s method, and is also a stronger evidence-deriving tool.
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objeCtives: To examine and explain differences and similarities in coverage 
decisions for outpatient pharmaceuticals in Denmark, Norway and Sweden, and 
to provide a better understanding of the current and future role of HTA in these 
countries. Methods: A comparative analysis of all outpatient drug appraisals 
carried out between 2009 and 2012, including an analysis of divergent coverage 
decisions for outpatient drug-indication pairs appraised by all three countries was 
performed. Agreement levels between HTA agencies were measured using kappa 
scores. Primary data collection through consultation with decision makers and 
academics in the three countries was carried out to obtain insight on how coverage 
decisions are made and why reimbursement outcomes differ in the three coun-
tries. Results: A total of 19 outpatient drug-indication pairs appraised in each of 
the three countries were identified, of which six pairs (32%) had divergent coverage 
decisions. An uneven distribution of coverage decisions was observed, with the 
highest number of overlap in appraisals in Norway and Sweden (freemarginal kappa 
0.89). Similarities were found in the criteria for reimbursement and the reasoning for 
coverage decisions. Differences in the appraisal methods applied and the interpreta-
tion of the evidence considered may explain divergent decisions. ConClusions: 
The study suggests that Norway and Sweden employ similar methods for outpatient 
drug appraisals and have less divergent reimbursement outcomes, while health 
economic evaluation is less prominent in Danish outpatient drug appraisal, leading 
to a lower percentage of reimbursements with restrictions or criteria.
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objeCtives: To assess the role of safety aspects in the overall AMNOG benefit 
assessment in Germany. Special attention was given to two aspects: (1) Are adverse 
events (AE) used systematically to change the benefit assessment in any direction? 
(2) Are safety aspects considered in the assessment in accordance with the scien-
tific CHMP opinion? Methods: Twenty-six benefit assessments decided and pub-
lished by the Federal Joint Committee (G-BA) between Jan 1st 2011 and Jun 6th2013 
were analyzed regarding the extent of harm. For each drug the extent of harm 
included with the consecutive influence on the overall benefit rating including 
potential changes in the overall rating scores was determined. Additionally, the 
safety aspects considered in the G-BA decision were compared to the CHMP assess-
ments. Results: For 19 of 26 drugs (73.1%), a greater or less harm vs. the compara-
tor determined by the G-BA was considered. In 12 of these 19 substances (63.2%) the 
rating of the additional benefit drawn from efficacy results remained unaltered due 
to safety aspects. In 5 procedures (26.3%) the G-BA rated the additional benefit solely 
on the basis of less harm vs. the comparator. In 2 procedures (10.5%) the G-BA found 
a greater harm vs. the comparator which negatively impacted the overall rating. 
Statistically significant results of ‘overall incidence of AE’, ‘AE grade 3-4’, ‘serious AE’ 
and ‘AE leading to study withdrawal’ were always considered by the G-BA. In 8 cases 
(42.0%), the G-BA weighted safety aspects differently from the EMA in its overall 
rating process. ConClusions: The AE profile is of major importance in the AMNOG 
process. It changed in more than one third of the drug assessments (7 cases; 36.8%) 
the efficacy based benefit ratings. In 8 cases (42.0%) the G-BA assessment deviated 
from the conclusions considered by the EMA.
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objeCtives: To understand the dynamics of the Transparency Committee (TC) 
assessments of monoclonal Antibodies (mAbs) through the improvement in ther-
apeutic benefit (known as “ASMR”) ratings from 2000 to 2012. ASMR ratings are 
divided into two main groups by the French health care system. ASMR I to III allow 
manufacturers to notify price to the pricing committee based on the innovative 
character of the product and on the improvement provided over standard of care. 
This allows pricing at the “European” level. ASMR IV and V are given to non-inno-
vative products adding at best minor improvement to standard of care. Methods: 
mAbs (excluding radiotherapeutics) online published reports from the TC from 2000 
to 2012, including new indications and reassessments, were analysed. The TC has 
evaluated a total of 26 mAbs, leading to 105 ASMR ratings during the period stud-
ied. Results: From 2000 to 2006, 83% (n = 29) of the TC evaluations of mAbs led 
to ASMR I, II or III and only 17% of the TC evaluation lead to ASMR IV or V (n = 6). 
During the following period, from 2006 to 2012, the TC granted only 30% (n = 21) of 
